Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP437 | DOI: 10.1530/endoabs.90.EP437

1University General Hospital of Valencia, Endocrinology, Diabetes and Nutrition, Valencia, Spain; 2General Hospital of Requena, Endocrinology, Diabetes and Nutrition, Requena, Spain; 3Medical Center of Picassent, Primary Care, Picassent, Spain


Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.

Methods: Retrospective real-world efficacy analysis including aGLP1-naïve adults with T2DM who were started on oral or subcutaneous semaglutide add-on to T2DM treatment during the year 2022. The primary outcome was change in HbA1c. Secondary outcomes were changes in weight and lipid profile, occurrence of gastrointestinal side effects (GSEs), and discontinuations. Linear mixed models were used to estimate changes in HbA1c, weight, and BMI, and logistic regression was used to analyze GSEs and discontinuations.

Results: 136 patients were included, 82 in the subcutaneous semaglutide group and 54 in the oral semaglutide group. Mean age was 60 years (SD 1.5) and HbA1c 8.2% (SD 0.2). At 24 weeks, the mean reductions in HbA1c were: -1.2% (SD 0.2) with subcutaneous semaglutide and -1.3% (SD 0.2) for oral semaglutide (p n.s). The mean changes in body weight from baseline to week 24 were: -5.5 kg (SE 2.3) for subcutaneous semaglutide and -6.9 kg (SD 2.4) for oral semaglutide, (p n.s ). There were no differences in the lipid profile. Some type of adverse event occurred in 41 patients in the subcutaneous semaglutide group (50%) and in 21 patients in the oral semaglutide group (39%), mostly mild gastrointestinal effects. There were 11 withdrawals from treatment in the subcutaneous semaglutide group (13.4%) and 5 in the oral semaglutide group (9.2%).

Conclusion: Semaglutide, in its two presentations (subcutaneous and oral) are effective in the treatment of patients with DM2. There were no differences in HbA1c, weight, or lipid profile, or in the appearance of adverse effects or dropouts.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.